Now i am giving you APOD

Revenue for the six months ended March 31,2003 was $22,235,501, an increase of $8,846,086 or 66.1% over the six months ended March 31,2002. The increase in revenue was due to an unusually large increase in the distribution of products to wholesale distributors. The Company does not know if they will be able to sustain this growth in future periods. Cost of sales for the six months ended March 31,2003 was $21,101,277, an increase of $8,987,138 or 74.2% over the six months ended March 31,2002. As a result the gross margin for the period ended March 31,2003 was $1,134,224 or 5.10% compared to $1,275,276 or 9.52% for the period ended March 31,2002. The decrease in the gross profit margin were a result of the increased revenue being wholesale products which have low profit margins and reduced revenue from the retail dental sales. Medical supply sales which have a higher gross profit margin than the wholesale sales have increased but have not yet made up for the decrease in the dental sales. The Company expects that the increases in sales of medical supplies will make up for the loss in dental sales and increase the Company's overall gross profit margin.

Selling expenses for the six months ended March 31,2003 were $267,288, a decrease of $130,575 or 32.8% compared to the six months ended March 31,2002. The Company has reduced shipping costs by $22,646; commissions by $42,314; and advertising costs by $110,997. Advertising costs in the next three to six months will increase as the Company brings out several new catalogues. Travel and entertainment expenses increased by $33,420, which is related directly to increased contact with medical and wholesale purchasers.

General and administrative expenses for the six months ended March 31,2003 increased by $63,685 or 8.0% from the six months ended March 31,2002. Total compensation including payroll taxes increased by approximately , 32,000 which included a bonus of $152,500 for one of the officers for attaining sales levels included in his employment agreement. Without this bonus, employment expenses would have decreased by approximately $120,500 which includes the reduction of two employees and voluntary salary reductions by the three officers of the Company Other increases included professional and financing fees, which increased by $21,484, primarily for the Company's new financing agreement. Insurance increased by $8,992 primarily from the increases in medical expenses. Other general and administrative expenses increased by approximately $8,500.

Interest expense for the six months ended March 31,2003 was $55,406, a decrease of $6,787 form the six month period ended March 31,2002. This was accomplished by entering into a new financing agreement where all collections are applied against the line of credit on a daily basis and proceeds from the line of credit are only taken when needed to pay down liabilities. As a result the average daily balance outstanding on the line of credit has been reduced. The new financing agreement allows the Company greater flexibility in its ability to finance increased sales and additional inventory.

APO Retains Consultant for Merger and Acquisitions
Thursday June 5, 4:19 pm ET http://biz.yahoo.com/bw/030605/55614_1.html

OCEANSIDE, N.Y.--(BUSINESS WIRE)--June 5, 2003--APO Health, Inc. (APO) (APOA), announced today that it has recently retained the services of a financial advisory consulting group that has been active in exploring the viability of merger and acquisition opportunities for the Company.
Additionally, this group is presenting the Company with recommendations for potential areas of expansion.

Jan Stahl, Chairman and CEO of APO Health, "As always, it is our intention to maintain and build value in the Company for the benefit of APO Health, Inc. and its shareholders."

http://www.apohealth.com/
COMPANY FACT SHEET

COMPANY: APO Health
BASE/LOCATION: Oceanside, NY
CONTACT: Dr. Jan Stahl, CEO and Vice President
PHONE: 516-594-0005
INVESTOR RELATIONS: Peter Steil, CFO 516 594-0005
SYMBOL: APOA
TRADED: OTC (Bulletin Board)
SHARES OUTSTANDING: OUTSTANDING: 22,004,000
PUBLIC SINCE: June 2001
LONG TERM DEBT: 0

SALES AND EARNINGS

2001E (FY ends 9-30-01)
$27-30 million
Gross Profit $3-3.5 million

KEY FACTS

Achieved competitive pricing from opportunistic inventory purchases and a strong sense of anticipating market demands by management.
Sales are expected to increase from active promotion of its dental, medical and veterinary division.
Introducing a unique first aid Dental Kit, allowing consumers to perform limited emergency dental procedures.
Wholesale division will continue to grow with medical, dental and consumer products.
Opening up a pharmaceutical division from which all physicians, dentists and veterinarians can purchase needed supplies.
Through new acquisitions, the company will be able to address the consolidation that is going on in the medical marketplace.
Significant new opportunities for the company's products exist with the emergency service industries, schools, camps and institutions.

Disclaimer: Information contained herein is based on sources we believe to be reliable but we do not guarantee its accuracy. Rev. 6-01